This combination strategy has not been evaluated yet in NSCLC clinical trials, probably considering the availability of agents able to block EGFR and HER-2 simultaneously, such as afatinib and dacomitinib [18]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.